Drugs / ELGN-2112
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05904626 Comparator | Oct 2025 → Jun 2027 expected | malabsorption syndrome | Elgan Pharma Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05670951 Comparator | Feb 2025 → Nov 2027 expected | malabsorption syndrome | Elgan Pharma Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-05 | Chiesi Farmaceutici S.p.A. | Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants chiesi.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELGN-2112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05670951 ↗ |
| Known as | Human insulin [rDNA] | “ELGN-2112 Human insulin [rDNA]” NCT05904626 ↗ |
| Modality | Protein / enzyme biologic | “ELGN-2112 Human insulin [rDNA]” NCT05904626 ↗ |